ArticleFrontiers in microbiology2025
The role of FTO in m6A RNA methylation and immune regulation in
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Propolis Flavonoids Ameliorate Chronic Osteomyelitis in a Rat Model by Modulating TAZ-Regulated Treg/Th17 Balance.Immunity, inflammation and disease · 2026Article
- FTO rs7195994 Is associated with TNF inhibitor response in lean rheumatoid arthritis patients: A BMI-stratified pharmacogenetic analysis.The pharmacogenomics journal · 2026Article
- FTO-engineered extracellular vesicles from bone marrow mesenchymal stem cells ameliorate Staphylococcus aureus-induced osteomyelitis via m6A-dependent suppression of autophagy and pyroptosis.Journal of biological engineering · 2025Article
- Exploring the gut microbiota-Parkinson's disease link: preliminary insights from metagenomics and Mendelian randomization.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Regulators of n6-methyladenosine (m6A) RNA modification play important roles in many diseases; however, their involvement in Methods: We downloaded the Results: We identified 19 co-expressed genes closely related to FTO were identified, along with 206 related transcription factor regulatory genes and 589 miRNAs. Enrichment analyses suggested that these genes were involved in pathways related to the proliferation and oxidation of various immune cells, cellular senescence, and various tumors and immune cells, as well as cell cycle-related functions. GSEA revealed that PD-1, TH1, TH2, CTLA4, and other pathways were significantly enriched in patients with high FTO expression. GSVA indicated that the differentially enriched pathways were related to included amino acid metabolism, immunity, and infection. Correlation analysis of immune infiltration revealed that monocytes, M2 macrophages, resting mast cells, and neutrophils were present in normal and diseased samples. Differences in expression were observed between the groups. The western blotting and qPCR analyses confirmed that the protein expression of FTO was reduced in macrophages after infection with Conclusion: The m6A RNA methylation regulator FTO may serve as a potential diagnostic marker and therapeutic target, involved in the pathogenesis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.